secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncotelic Therapeutics, Inc. (OTLC)
CIK:        0000908259
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0001493152-26-013503
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncotelic subsidiary Sapu Nano unveils Deciparticle platform; two Phase 1 assets at BIO-Europe
--------------------------------------------------------------------------------

- Sapu Nano to present Deciparticle platform and clinical pipeline at BIO-Europe Spring 2026 on March 25.
- Two lead candidates: Sapu003 (everolimus IV) in Phase 1, Sapu006 (docetaxel) entering Phase 1.
- Deciparticle is sub-20 nm nanomedicine for hydrophobic drugs, aiming to improve PK and reduce toxicities.
- Sapu Nano seeking strategic partnerships to accelerate development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/908259/000149315226013503/0001493152-26-013503-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/908259/000149315226013503/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-013503

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer